The pharmaceutical group Johnson & Johnson confirms an effective reduction in Switzerland on information Published inside Paradeplatz If January 3. The German website confirmed that the American giant deleted 100 posts and closed the Zuchel website in the canton of Soleur. If Johnson & Johnson decides to restructure AWP, it has declined to provide a salary related to the number of positions involved.
It has successfully adapted to a complex and rapidly evolving external environment, and an open door has been announced after the end of the AWP period. The company has recently begun making adjustments to its organization to improve the process. The relevant employees will be able to assist during their search for a new job, as well as the finer details held by the agency.
The group has a presence in New Brunswick through the United States and indicates it has 5,600 employees in Switzerland (131,900 total by the end of 2023) across different portfolios and new locations. Celui de Zuchwil évoqué par Inside Paradeplatz, is the siege of activities in EMEA (Europe, Middle East and Africa) of DePuy Synthes, a division specializing in orthopedic products. The presence in Switzerland dates back to 1959 with the Cilag excursion to the Schaffhouse, which today is the country’s main production site.
320 recently deleted posts
In 2021, the American group recently announced the abolition of 320 jobs with more than 300 employees in the canton of Neuchâtel due to the transfer of some activities to Mexico and Costa Rica. A decision that will lead to a strong reaction, the group refuses to make a social plan. Additional political figures are also demanding compensation for aides and financial compensation that Johnson & Johnson did not benefit from.
During the pandemic, the American group was the first to propose a vaccine against the coronavirus. In contrast to the ARNm de Pfizer/BioNTech and Moderna vaccines, Johnson & Johnson is rethinking old technology. This use has been suspended for some time due to secondary effects and the group decided not to continue development in order to counter the new variants.
In 2023, the group recorded a turnover of $85.1 billion (compared to $79.9 billion in 2022). This was also achieved by an increase of up to 35,1 billion (17,9 in 2022). This progress was demonstrated by the introduction of the Kenvue exchange, an old division of the group’s public health products. Without this activity, the benefit of Johnson & Johnson appears In the first quarter of 2024, its new capital will reach $10.6 billion (9.2% in the same period of 2023).
adxpro.online